OVARIAN CANCER RECURRENT
Clinical trials for OVARIAN CANCER RECURRENT explained in plain language.
Never miss a new study
Get alerted when new OVARIAN CANCER RECURRENT trials appear
Sign up with your email to follow new studies for OVARIAN CANCER RECURRENT, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Antibody-Drug combo takes aim at Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis study tests a new drug called raludotatug deruxtecan (R-DXd) in people whose high-grade serous ovarian, peritoneal, or fallopian tube cancer has returned after platinum chemotherapy. R-DXd is an antibody-drug conjugate that seeks out cancer cells and delivers a toxic payload…
Matched conditions: OVARIAN CANCER RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New antibody COM701 aims to keep ovarian cancer at bay
Disease control Recruiting nowThis clinical trial tests whether the experimental antibody COM701 can delay the return of ovarian cancer in people whose cancer has come back but still responds to platinum chemotherapy. About 60 participants will receive COM701 or a placebo every three weeks as maintenance ther…
Matched conditions: OVARIAN CANCER RECURRENT
Phase: PHASE1, PHASE2 • Sponsor: Compugen Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Engineered immune cells take on tough ovarian cancer in first human trial
Disease control Recruiting nowThis early-stage trial is testing a one-time treatment called OPB-101 for women with ovarian cancer that no longer responds to platinum chemotherapy. The therapy uses a patient's own immune cells (T cells) that are modified in a lab to better recognize and attack cancer cells, pl…
Matched conditions: OVARIAN CANCER RECURRENT
Phase: PHASE1 • Sponsor: Outpace Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC